Esterase activity of carbonic anhydrases serves as surrogate for selecting antibodies blocking hydratase activity

References

• Lindskog S. Structure and mechanism of carbonic anhydrase. Pharmacol Therapeut 1997;74:1–20
   PubMed Web of Science ®Google Scholar
• Breton S. The cellular physiology of carbonic anhydrases. JOP 2001;2:159–64
   PubMedGoogle Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77
   PubMed Web of Science ®Google Scholar
• Chiche J, Ilc K, Laferriere J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009;69:358–68
   PubMed Web of Science ®Google Scholar
• Swietach P, Wigfield S, Cobden P, et al. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem 2008;283:20473–83
   PubMed Web of Science ®Google Scholar
• Swietach P, Patiar S, Supuran C, et al. The role of carbonic anhydrase 9 in regulating extracellular and intracellular pH in three-dimensional tumor cell growths. J Biol Chem 2009;284:20299–310
   PubMed Web of Science ®Google Scholar
• Svastova E, Hulikova A, Rafajova M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004;577:439–45
   PubMed Web of Science ®Google Scholar
• Pastorek J, Pastorekova S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994;9:2877–88
   PubMed Web of Science ®Google Scholar
• Zavada J, Zavadova Z, Pastorekova S, et al. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 1993;54:268–74
   PubMed Web of Science ®Google Scholar
• Tureci O, Sahin U, Vollmar E, et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci USA 1998;95:7608–13
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81
   PubMed Web of Science ®Google Scholar
• Zavada J, Zavadova Z, Pastorek J, et al. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 2000;82:1808–13
   PubMed Web of Science ®Google Scholar
• Chrastina A, Zavada J, Parkkila S, et al. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. International journal of cancer J Int du Cancer 2003;105:873–81
   PubMed Web of Science ®Google Scholar
• Chrastina A, Pastorekova S, Pastorek J. Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody. Neoplasma 2003;50:13–21
   PubMed Web of Science ®Google Scholar
• Battke C, Kremmer E, Mysliwietz J, et al. Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII. Cancer Immunol Immunother 2011;60:649–58
   PubMed Web of Science ®Google Scholar
• Oosterwijk-Wakka JC, Boerman OC, Mulders PF, Oosterwijk E. Application of Monoclonal antibody g250 recognizing carbonic anhydrase ix in renal cell carcinoma. Int J Mol Sci 2013;14:11402–23
   PubMed Web of Science ®Google Scholar
• Muselaers CH, Oosterwijk E, Bos DL, et al. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model. Mol Imaging 2014;13:1–7
   PubMed Web of Science ®Google Scholar
• Muselaers CHJ, Stillebroer AB, Desar IME, et al. Tyrosine kinase inhibitor sorafenib decreases 111in-girentuximab uptake in patients with clear cell renal cell carcinoma. J Nucl Med 2014;55:242–7
   PubMed Web of Science ®Google Scholar
• Arie S, Belldegrun KC, Kloepfer P, et al. A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC—Results and implications for adjuvant clinical trials. J Clin Oncol 2013;31:4507
   Google Scholar
• Gondi G, Mysliwietz J, Hulikova A, et al. Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII. Cancer Res 2013;73:6494–503
   PubMed Web of Science ®Google Scholar
• Dekaminaviciute D, Kairys V, Zilnyte M, et al. Monoclonal antibodies raised against 167–180 aa sequence of human carbonic anhydrase XII inhibit its enzymatic activity. J Enzyme Inhib Med Chem 2014;29:804–10
   PubMed Web of Science ®Google Scholar
• Murri-Plesko M, Hulikova A, Oosterwijk E, et al. Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX. Eur J Pharmacol 2011;657:173–83
   PubMed Web of Science ®Google Scholar
• Xu C, Lo A, Yammanuru A, et al. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One 2010;5:e9625
   Google Scholar
• Krishnamurthy VM, Kaufman GK, Urbach AR, et al. Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev 2008;108:946–1051
   PubMed Web of Science ®Google Scholar
• Verpoorte JA, Mehta S, Edsall JT. Esterase activities of human carbonic anhydrases B and C. J Biol Chem 1967;242:4221–9
   PubMed Web of Science ®Google Scholar
• Tashian RE, Douglas DP, Yu Y-SL. Esterase and hydrase activity of carbonic anhydrase-I from primate erythrocytes. Biochem Biophys Res Commun 1964;14:256–61
   PubMed Web of Science ®Google Scholar
• Gould SM, Tawfik DS. Directed evolution of the promiscuous esterase activity of carbonic anhydrase II. Biochemistry 2005;44:5444–52
   PubMed Web of Science ®Google Scholar
• Fierke CA, Calderone TL, Krebs JF. Functional consequences of engineering the hydrophobic pocket of carbonic anhydrase II. Biochemistry. 1991;30:11054–63
   PubMed Web of Science ®Google Scholar
• Elleby B, Sjöblom B, Lindskog S. Changing the efficiency and specificity of the esterase activity of human carbonic anhydrase II by site-specific mutagenesis. Eur J Biochem 1999;262:516–21
   PubMedGoogle Scholar
• Alexander RS, Nair SK, Christianson DW. Engineering the hydrophobic pocket of carbonic anhydrase II. Biochemistry 1991;30:11064–72
   PubMed Web of Science ®Google Scholar
• Alexander RS, Kiefer LL, Fierke CA, Christianson DW. Engineering the zinc binding site of human carbonic anhydrase II: structure of the His-94→Cys apoenzyme in a new crystalline form. Biochemistry 1993;32:1510–8. PubMed PMID: 8431430
   PubMed Web of Science ®Google Scholar
• Lopez M, Vu H, Wang CK, et al. Promiscuity of carbonic anhydrase II. Unexpected ester hydrolysis of carbohydrate-based sulfamate inhibitors. J Am Chem Soc 2011;133:18452–62
   PubMed Web of Science ®Google Scholar
• Kasimogullari R, Bulbul M, Gunhan H, Guleryuz H. Effects of new 5-amino-1,3,4-thiadiazole-2-sulfonamide derivatives on human carbonic anhydrase isozymes. Bioorg Med Chem 2009;17:3295–301
   PubMed Web of Science ®Google Scholar
• Iyer R, Barrese AA, IIIrd Parakh S, et al. Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds. J Biomol Screening 2006;11:782–91
   PubMed Web of Science ®Google Scholar
• Ekinci D, Beydemir S, Alim Z. Some drugs inhibit in vitro hydratase and esterase activities of human carbonic anhydrase-I and II. Pharmacol Rep 2007;59:580–7
   PubMed Web of Science ®Google Scholar
• Ekinci D, Karagoz L, Ekinci D, et al. Carbonic anhydrase inhibitors: in vitro inhibition of alpha isoforms (hCA I, hCA II, bCA III, hCA IV) by flavonoids. J Enzyme Inhib Med Chem 2013;28:283–8
   PubMed Web of Science ®Google Scholar
• Akincioglu A, Akbaba Y, Gocer H, et al. Novel sulfamides as potential carbonic anhydrase isoenzymes inhibitors. Bioorg Med Chem 2013;21:1379–85
   PubMed Web of Science ®Google Scholar
• Bayram E, Senturk M, Kufrevioglu OI, Supuran CT. In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem 2008;16:9101–5
   PubMed Web of Science ®Google Scholar